Menu
Caravel Oculus Inc. was founded by a team of professionals with extensive experience in pharmaceutical marketing, focusing on the development of ophthalmic drugs.
We aim to address unmet clinical needs by advancing treatment options and delivering safe, effective, and clinically valuable new therapies that improve the quality of life for patients with eye diseases worldwide.
2026.7.17
Caravel Oculus Advances Novel Corneal Drug CA201A Globally with Phase II Trial Recruitment in Australia
2025.6.5
Our company convened the 2025 annual shareholders’ meeting
PIPELINE
Drawing on years of clinical experience, a group of ophthalmology professors observed that certain existing drug compounds hold potential for further research and development in diseases with no current treatment options. This insight led them to explore additional product opportunities with strong development potential.